08/31/23 6:45 AM
OTC : MNKTQ
fda approvallow float
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
Mallinckrodt plc, a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, 2023 from the United States Food and Drug Administration for its Abbreviated New Drug Application for Lisdexamfetamine Dimesylate Capsules 10 mg, 20 mg, 30...
Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023.. As expected, the Court granted Mallinckrodt...